Profile data is unavailable for this security.
About the company
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
- Revenue in USD (TTM)539.00k
- Net income in USD-72.33m
- Incorporated2017
- Employees61.00
- LocationCG Oncology Inc400 Spectrum Center Drive, Suite 2040IRVINE 92618United StatesUSA
- Phone+1 (949) 288-6298
- Fax+1 (302) 531-3150
- Websitehttps://www.cgoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Keros Therapeutics Inc | 234.00k | -160.30m | 1.89bn | 141.00 | -- | 4.16 | -- | 8,067.99 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Akero Therapeutics Inc | 0.00 | -179.27m | 1.94bn | 58.00 | -- | 2.30 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
Vera Therapeutics Inc | 0.00 | -94.30m | 2.01bn | 55.00 | -- | 5.65 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
Arvinas Inc | 71.30m | -354.80m | 2.03bn | 445.00 | -- | 3.32 | -- | 28.46 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 2.04bn | 278.00 | -- | 8.69 | -- | 9.12 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 2.06bn | 120.00 | -- | 4.84 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 2.08bn | 112.00 | -- | 4.23 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
CG Oncology Inc | 539.00k | -72.33m | 2.20bn | 61.00 | -- | 3.87 | -- | 4,088.66 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.20bn | 111.00 | -- | 4.19 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.28bn | 500.00 | -- | 4.94 | -- | 49.28 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.28bn | 64.00 | -- | 3.48 | -- | 313.01 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.30bn | 268.00 | -- | 5.20 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.31bn | 570.00 | -- | 5.62 | -- | 8.42 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 2.36bn | 124.00 | 16.38 | 4.21 | 14.49 | 7.50 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Novavax Inc | 996.61m | -398.71m | 2.40bn | 1.54k | -- | -- | -- | 2.41 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Fortrea Holdings Inc | 3.01bn | -100.60m | 2.41bn | 16.00k | -- | 1.51 | -- | 0.8004 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Ally Bridge Group (NY) LLCas of 25 Jan 2024 | 2.49m | 3.74% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.19m | 3.29% |
BVF Partners LPas of 31 Mar 2024 | 1.88m | 2.83% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.54m | 2.31% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.52m | 2.28% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.45m | 2.18% |
RA Capital Management LPas of 31 Mar 2024 | 1.40m | 2.10% |
Perceptive Advisors LLCas of 31 Mar 2024 | 1.30m | 1.96% |
Braidwell LPas of 31 Mar 2024 | 1.13m | 1.70% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 975.12k | 1.46% |